Modality
Peptide
MOA
WRNi
Target
DLL3
Pathway
Autophagy
AS
Development Pipeline
Preclinical
~Sep 2016
→ ~Dec 2017
Phase 1
Mar 2018
→ Sep 2031
Phase 1Current
NCT05331407
863 pts·AS
2024-12→2031-09·Recruiting
NCT03525718
496 pts·AS
2018-03→2027-03·Recruiting
1,359 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-0611mo awayPh2 Data· AS
2031-09-285.5y awayPh2 Data· AS
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Recruit…
P1/2
Recruit…
Catalysts
Ph2 Data
2027-03-06 · 11mo away
AS
Ph2 Data
2031-09-28 · 5.5y away
AS
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05331407 | Phase 1/2 | AS | Recruiting | 863 | PASI75 |
| NCT03525718 | Phase 1/2 | AS | Recruiting | 496 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| REG-7737 | Regeneron | Preclinical | CD123 |